New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Muscular Dystrophy (MD) is a genetic condition causing progressive muscle weakness and complications in vital organs. Early diagnosis, multidisciplinary care, and emerging treatments like gene therapy ...

Researchers link early cone dysfunction in RPGR-related retinal dystrophy to high myopia, with timing of degeneration influencing severity and outcomes.

Unlike the skeletal muscle degenerative process, for which treatment options are currently limited, therapy is available for the cardiovascular complications that accompany muscular dystrophy.

The U.S. Food and Drug Administration declined to approve Capricor Therapeutics' cell therapy for a heart condition and asked ...

Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...

The molecular changes that lead to Fuchs' endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research shows.

New vitamin-based treatment that could reduce muscle degeneration in muscular dystrophy. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2012 / 10 / 121023172109.htm ...

Mutations in peripherin 2 are associated with a variety of retinal degenerative diseases, including retinitis pigmentosa, cone-rod dystrophy and multiple forms of macular dystrophy.